Package Leaflet: Information for the User
Niapelf 25 mg prolonged-release injectable suspension
Niapelf 50 mg prolonged-release injectable suspension
Niapelf 75 mg prolonged-release injectable suspension
Niapelf 100 mg prolonged-release injectable suspension
Niapelf 150 mg prolonged-release injectable suspension
Paliperidone
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack:
Niapelf contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics, and is used as maintenance treatment for symptoms of schizophrenia in adult patients who have been stabilized on paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may start treatment with Niapelf without prior stabilization on paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are not normally present. For example, a person with schizophrenia may hear voices or see things that do not exist (called hallucinations), have false beliefs (called delusions), or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimulus or may have problems speaking in a clear and logical manner. People with this disorder may also feel depressed, anxious, guilty, or tense.
Paliperidone can help alleviate the symptoms of your illness and prevent them from coming back.
Do not use Niapelf
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using Niapelf.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with other similar medicines may have an increased risk of stroke or death (see section 4, possible side effects).
All medicines can cause side effects, and some of the side effects of this medicine may worsen the symptoms of other conditions. For this reason, it is important that you discuss with your doctor any of the following conditions that may worsen during treatment with this medicine:
If you have any of these conditions, please consult your doctor, as it may be necessary to adjust your dose or keep you under observation for a period of time.
Because it has been rarely observed in patients treated with this medicine that there is a dangerously low number of a type of white blood cell necessary to fight infections in the blood, your doctor may check your white blood cell count.
Even if you have previously tolerated oral paliperidone or risperidone, allergic reactions rarely occur after receiving paliperidone injections. Seek medical help immediately if you experience a skin rash, swelling of the throat, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medicine, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, and your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medicine can reduce the urge to vomit, there is a possibility that it may mask the normal response of the body to the ingestion of toxic substances or other conditions.
During eye surgery for cataracts, the pupil (the black circle in the center of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause damage to the eye. If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in children under 18 years of age.
Other medicines and Niapelf
Tell your doctor if you are using, have recently used, or might use any other medicines.
Taking this medicine with carbamazepine (an anti-epileptic and mood stabilizer) may require a change in your dose of this medicine.
Since this medicine acts mainly on the brain, interaction with other medicines that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medicines, opioids, antihistamines, and sleeping medicines.
Since this medicine can lower blood pressure, you should be careful if you use this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless legs syndrome (e.g., levodopa).
This medicine may cause an abnormality in the electrocardiogram (ECG) that shows that it is necessary to have a prolonged period for an electrical impulse to travel through a certain part of the heart (known as "prolongation of the QT interval"). Other medicines that have this effect include some medicines used to treat heart rhythm or to treat infections, in addition to other antipsychotics.
If you are prone to seizures, this medicine may increase your chances of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infections, in addition to other antipsychotics.
Niapelf should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Niapelf with alcohol
Alcohol should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. You should not use this medicine during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (the last three months of pregnancy): tremor, stiffness and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
This medicine can pass from mother to child through breast milk and may harm the baby. Therefore, you should not breastfeed while using this medicine.
Driving and using machines
During treatment with this medicine, dizziness, extreme fatigue, and vision problems (see section 4) may occur. This should be taken into account when maximum attention is required, e.g., when driving or operating machinery.
Niapelf contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
Your doctor or another healthcare professional will administer this medicine to you. Your doctor will tell you when you should receive the next injection. It is important that you do not miss any of your scheduled doses. If you are unable to attend your appointment with your doctor, make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medicine in the upper arm approximately one week apart. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
If your doctor is switching you from risperidone long-acting injection to this medicine, you will receive the first injection of this medicine (of 25 mg to 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (of 25 mg to 150 mg) in the upper arm or buttocks once a month.
Depending on your symptoms, your doctor may increase or decrease the amount of medicine you receive at the time of the monthly scheduled injection.
Patients with kidney problems
Your doctor may adjust the dose of this medicine according to your kidney function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medicine if you have moderate or severe kidney problems.
Elderly patients
Your doctor may reduce the dose of this medicine if your kidney function is decreased.
If you receive more Niapelf than you should
You will receive this medicine under medical supervision; it is therefore unlikely that you will receive an excessive dose.
Patient who have received an overdose of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heartbeat, low blood pressure, abnormal electrocardiogram (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you stop using Niapelf
If you stop receiving your injections, the effects of the medicine will be lost. You should not stop using this medicine unless your doctor tells you to, as your symptoms may come back.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Inform your doctor immediately if:
The following adverse effects may occur:
Very Common Adverse Effects: may affect more than 1 in 10 patients
Common Adverse Effects: may affect up to 1 in 10 patients
Uncommon Adverse Effects: may affect up to 1 in 100 patients
Rare Adverse Effects: may affect up to 1 in 1,000 patients
Frequency Not Known: cannot be estimated from the available data
Reporting of Adverse Effects
If you experience any adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V.
By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Niapelf Composition
The active ingredient is paliperidone.
Each 25 mg Niapelf pre-filled syringe contains 39 mg of paliperidone palmitate.
Each 50 mg Niapelf pre-filled syringe contains 78 mg of paliperidone palmitate.
Each 75 mg Niapelf pre-filled syringe contains 117 mg of paliperidone palmitate.
Each 100 mg Niapelf pre-filled syringe contains 156 mg of paliperidone palmitate.
Each 150 mg Niapelf pre-filled syringe contains 234 mg of paliperidone palmitate.
The other components are:
Polysorbate 20
Macrogol
Citric acid monohydrate (E-330)
Disodium phosphate
Sodium dihydrogen phosphate dihydrate
Sodium hydroxide (E-524)
Water for injectable preparations
Product Appearance and Container Contents
Niapelf is a white to off-white prolonged-release injectable suspension, supplied in a pre-filled syringe.
Each container contains 1 pre-filled syringe and 2 needles.
Treatment Initiation Pack:
Each container contains 1 Niapelf 150 mg container and 1 Niapelf 100 mg container.
Only certain pack sizes may be marketed.
Marketing Authorisation Holder
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí
Barcelona
Spain
Manufacturer
Neuraxpharm Pharmaceuticals, S.L.
Avda. Barcelona 69
08970 Sant Joan Despí
Barcelona
Spain
Neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Strasse 23
Richrath, Langenfeld (Rheinland)
40764 Germany
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder.
België/Belgique/Belgien Neuraxpharm Belgium Tel: +32 (0)2 732 56 95 | Lietuva Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 | Luxembourg/Luxemburg Neuraxpharm France Tel: +32 474 62 24 24 |
Ceská republika Neuraxpharm Bohemia s.r.o. Tel: +420 739 232 258 | Magyarország Neuraxpharm Hungary Kft. Tel: +36 (30) 542 2071 |
Danmark Neuraxpharm Sweden AB Tlf: +46 (0)8 30 91 41 (Sverige) | Malta Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Deutschland Neuraxpharm Arzneimittel GmbH Tel: +49 2173 1060 0 | Nederland Neuraxpharm Netherlands B.V Tel: +31 70 208 5211 |
Eesti Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 | Norge Neuraxpharm Sweden AB Tlf: +46 (0)8 30 91 41 |
Ελλάδα Brain Therapeutics IKE Τηλ: +302109931458 | Österreich Neuraxpharm Austria GmbH Tel: +43 2236 320038 |
España Neuraxpharm Spain, S.L.U. Tel: +34 93 475 96 00 | Polska Neuraxpharm Polska Sp. z.o.o. Tel: +48 783 423 453 |
France Neuraxpharm France Tel: +33 1.53.62.42.90 | Portugal Neuraxpharm Portugal, Unipessoal Lda Tel: +351 910 259 536 |
Hrvatska Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 602 24 21 | România Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Ireland Neuraxpharm Ireland Ltd. Tel: +353 1 428 7777 | Slovenija Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 |
Ísland Neuraxpharm Sweden AB Sími: +46 (0)8 30 91 41 (Svíþjóð) | Slovenská republika Neuraxpharm Slovakia a.s Tel: +421 255 425 562 |
Italia Neuraxpharm Italy S.p.A. Tel: +39 0736 980619 | Suomi/Finland Neuraxpharm Sweden AB Puh/ Tel: +46 (0)8 30 91 41 (Ruotsi/Sverige) |
Κύπρος Brain Therapeutics ΙΚΕ Τηλ: +302109931458 | Sverige Neuraxpharm Sweden AB Tel: +46 (0)8 30 91 41 |
Latvija Neuraxpharm Pharmaceuticals, S.L. Tel: +34 93 475 96 00 | United Kingdom (Northern Ireland) Neuraxpharm Ireland Ltd. Tel: +353 1 428 7777 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu
This information is intended for healthcare professionals only and should be read in conjunction with the full prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected for any foreign particles before administration. Do not use the product if the syringe is not visually free from foreign particles.
The container contains a pre-filled syringe and two safety needles (one 22-gauge, 1½-inch [38.1 mm x 0.72 mm] needle and one 23-gauge, 1-inch [25.4 mm x 0.64 mm] needle) for intramuscular injection. Niapelf is also available in a Treatment Initiation Pack, which contains two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first initiation dose of Niapelf (150 mg) is administered on Day 1 in the DELTOID muscle using the needle for DELTOID injection. The second initiation dose of Niapelf (100 mg) is also administered in the DELTOID muscle one week later (Day 8) using the needle for DELTOID injection.
If a patient is switched from prolonged-release injectable risperidone to Niapelf, the first Niapelf injection (dose range 25 mg to 150 mg) can be administered in the DELTOID muscle or the GLUTEAL muscle, using the appropriate needle for the injection site, at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in either the DELTOID muscle or the GLUTEAL muscle using the appropriate needle for the injection site.
In the case of DELTOID injection, if the patient weighs <90 kg, use the 23-gauge, 1-inch (25.4 mm x 0.64 mm) needle (needle with blue hub); if patient weighs ≥ 90 22-gauge, 1½-inch (38.1 0.72 gray hub).< p>
In the case of GLUTEAL injection, use the 22-gauge, 1½-inch (38.1 mm x 0.72 mm) needle (needle with gray hub).
Disposal of unused medicinal products and all materials that have come into contact with them should be done in accordance with local regulations.